Figure 2From: A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors Progression-free survival (PFS). (A) Kaplan-Meier estimation of PFS of all nine patients; and (B) difference in median PFS between five patients with primary progressive disease (PPD) and four with secondary progressive disease (SPD) or relapse (P = 0.018).Back to article page